Valneva SE (VLS.PA)
3.79EUR
25 Apr 2018
€0.03 (+0.80%)
€3.76
€3.75
€3.80
€3.75
116,884
203,997
€3.93
€2.49
About
Overall
| Beta: | 1.90 |
| Market Cap(Mil.): | €294.82 |
| Shares Outstanding(Mil.): | 77.58 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| VLS.PA | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 178.44 | 32.31 |
| EPS (TTM): | -0.15 | -- | -- |
| ROI: | -7.18 | -0.73 | 12.97 |
| ROE: | -11.92 | -2.77 | 14.84 |
BRIEF-Valneva FY Net Loss Narrows To 11.5 Million Euros
* EXPECTS DOUBLE-DIGIT PRODUCT SALES GROWTH TO CONTINUE IN 2018
BRIEF-Valneva Says No Safety Concerns Associated With VLA15 In Any Treatment Group
* NO SAFETY CONCERNS ASSOCIATED WITH VLA15 IN ANY TREATMENT GROUP
BRIEF-Valneva Reports Positive Phase I Interim Results For Its Lyme Vaccine Candidate VLA15
* VALNEVA REPORTS POSITIVE PHASE I INTERIM RESULTS FOR ITS LYME VACCINE CANDIDATE VLA15 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
BRIEF-Valneva Reports Positive Phase I Interim Results For Its Lyme Vaccine Candidate Vla15
* REG-VALNEVA REPORTS POSITIVE PHASE I INTERIM RESULTS FOR ITS LYME VACCINE CANDIDATE VLA15
BRIEF-Valneva Initiates Phase I Clinical Study Of Vaccine Candidate Against Chikungunya
* REG-VALNEVA INITIATES PHASE I CLINICAL STUDY TO EVALUATE ITS SINGLE-SHOT VACCINE CANDIDATE AGAINST CHIKUNGUNYA
BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus
* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS
BRIEF-Valneva Total Revenues Up At 109.8 Million Euros
* TOTAL REVENUES OF EUR 109.8 MILLION IN 2017 (2016 - EUR 97.9 MILLION)
BRIEF-Valneva Expands Its Commercial Operations And Establishes US Infrastructure
* REG-VALNEVA EXPANDS ITS COMMERCIAL OPERATIONS AND ESTABLISHES US INFRASTRUCTURE Source text for Eikon: Further company coverage: (Gdynia Newsroom)
BRIEF-Valneva 9M EBITDA increases to 12.3 million euros
* TOTAL REVENUES OF €79.8 MILLION IN FIRST NINE MONTHS 2017 VERSUS TO €70.7 MILLION YEAR AGO
BRIEF-Valneva signs contract with US government
* ANNOUNCED ON TUESDAY SIGNATURE OF $39.6 MILLION IXIARO SUPPLY CONTRACT WITH US GOVERNMENT
Estimates